London, United Kingdom–(Newsfile Corp. – February 19, 2021) – Awakn Life Sciences Inc. announces today the publication of results from its CMO Dr. Ben Sessa’s Bristol Imperial MDMA in Alcoholism (BIMA) trial, an open-label safety, tolerability and proof-of-concept study investigating the potential role for MDMA-Assisted Psychotherapy in treating patients with alcohol use disorder (AUD).


Previous articlePure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) Closer to Pure Mushrooms Sales with Company Code, NPN Submission
Next articleThe Benefits of Mescaline: How An Ancient Cactus Became a Future Medicine